In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity

Craig S. Brown, Michael S. Lee, Daisy W. Leung, Tianjiao Wang, Wei Xu, Priya Luthra, Manu Anantpadma, Reed S. Shabman, Lisa M. Melito, Karen S. Macmillan, Dominika M. Borek, Zbyszek Otwinowski, Parameshwaran Ramanan, Alisha J. Stubbs, Dayna S. Peterson, Jennifer M. Binning, Marco Tonelli, Mark A. Olson, Robert A. Davey, Joseph M. ReadyChristopher F. Basler, Gaya K. Amarasinghe

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The Ebola virus (EBOV) genome only encodes a single viral polypeptide with enzymatic activity, the viral large (L) RNA-dependent RNA polymerase protein. However, currently, there is limited information about the L protein, which has hampered the development of antivirals. Therefore, antifiloviral therapeutic efforts must include additional targets such as protein-protein interfaces. Viral protein 35 (VP35) is multifunctional and plays important roles in viral pathogenesis, including viral mRNA synthesis and replication of the negative-sense RNA viral genome. Previous studies revealed that mutation of key basic residues within the VP35 interferon inhibitory domain (IID) results in significant EBOV attenuation, both in vitro and in vivo. In the current study, we use an experimental pipeline that includes structure-based in silico screening and biochemical and structural characterization, along with medicinal chemistry, to identify and characterize small molecules that target a binding pocket within VP35. NMR mapping experiments and high-resolution x-ray crystal structures show that select small molecules bind to a region of VP35 IID that is important for replication complex formation through interactions with the viral nucleoprotein (NP). We also tested select compounds for their ability to inhibit VP35 IID-NP interactions in vitro as well as VP35 function in a minigenome assay and EBOV replication. These results confirm the ability of compounds identified in this study to inhibit VP35-NP interactions in vitro and to impair viral replication in cell-based assays. These studies provide an initial framework to guide development of antifiloviral compounds against filoviral VP35 proteins.

Original languageEnglish (US)
Pages (from-to)2045-2058
Number of pages14
JournalJournal of Molecular Biology
Volume426
Issue number10
DOIs
StatePublished - May 15 2014

Fingerprint

Viral Proteins
Computer Simulation
Ebolavirus
Nucleoproteins
Proteins
Interferons
RNA Replicase
Pharmaceutical Chemistry
Viral Genome
Virus Replication
Antiviral Agents
X-Rays
Genome
RNA
Messenger RNA
Peptides
Mutation
In Vitro Techniques

Keywords

  • antivirals
  • filoviral inhibitors
  • in silico drug discovery
  • VP35

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Brown, C. S., Lee, M. S., Leung, D. W., Wang, T., Xu, W., Luthra, P., ... Amarasinghe, G. K. (2014). In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. Journal of Molecular Biology, 426(10), 2045-2058. https://doi.org/10.1016/j.jmb.2014.01.010

In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. / Brown, Craig S.; Lee, Michael S.; Leung, Daisy W.; Wang, Tianjiao; Xu, Wei; Luthra, Priya; Anantpadma, Manu; Shabman, Reed S.; Melito, Lisa M.; Macmillan, Karen S.; Borek, Dominika M.; Otwinowski, Zbyszek; Ramanan, Parameshwaran; Stubbs, Alisha J.; Peterson, Dayna S.; Binning, Jennifer M.; Tonelli, Marco; Olson, Mark A.; Davey, Robert A.; Ready, Joseph M.; Basler, Christopher F.; Amarasinghe, Gaya K.

In: Journal of Molecular Biology, Vol. 426, No. 10, 15.05.2014, p. 2045-2058.

Research output: Contribution to journalArticle

Brown, CS, Lee, MS, Leung, DW, Wang, T, Xu, W, Luthra, P, Anantpadma, M, Shabman, RS, Melito, LM, Macmillan, KS, Borek, DM, Otwinowski, Z, Ramanan, P, Stubbs, AJ, Peterson, DS, Binning, JM, Tonelli, M, Olson, MA, Davey, RA, Ready, JM, Basler, CF & Amarasinghe, GK 2014, 'In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity', Journal of Molecular Biology, vol. 426, no. 10, pp. 2045-2058. https://doi.org/10.1016/j.jmb.2014.01.010
Brown, Craig S. ; Lee, Michael S. ; Leung, Daisy W. ; Wang, Tianjiao ; Xu, Wei ; Luthra, Priya ; Anantpadma, Manu ; Shabman, Reed S. ; Melito, Lisa M. ; Macmillan, Karen S. ; Borek, Dominika M. ; Otwinowski, Zbyszek ; Ramanan, Parameshwaran ; Stubbs, Alisha J. ; Peterson, Dayna S. ; Binning, Jennifer M. ; Tonelli, Marco ; Olson, Mark A. ; Davey, Robert A. ; Ready, Joseph M. ; Basler, Christopher F. ; Amarasinghe, Gaya K. / In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. In: Journal of Molecular Biology. 2014 ; Vol. 426, No. 10. pp. 2045-2058.
@article{ff27a4e4e84a4a0dba6c49b1335d5cf9,
title = "In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity",
abstract = "The Ebola virus (EBOV) genome only encodes a single viral polypeptide with enzymatic activity, the viral large (L) RNA-dependent RNA polymerase protein. However, currently, there is limited information about the L protein, which has hampered the development of antivirals. Therefore, antifiloviral therapeutic efforts must include additional targets such as protein-protein interfaces. Viral protein 35 (VP35) is multifunctional and plays important roles in viral pathogenesis, including viral mRNA synthesis and replication of the negative-sense RNA viral genome. Previous studies revealed that mutation of key basic residues within the VP35 interferon inhibitory domain (IID) results in significant EBOV attenuation, both in vitro and in vivo. In the current study, we use an experimental pipeline that includes structure-based in silico screening and biochemical and structural characterization, along with medicinal chemistry, to identify and characterize small molecules that target a binding pocket within VP35. NMR mapping experiments and high-resolution x-ray crystal structures show that select small molecules bind to a region of VP35 IID that is important for replication complex formation through interactions with the viral nucleoprotein (NP). We also tested select compounds for their ability to inhibit VP35 IID-NP interactions in vitro as well as VP35 function in a minigenome assay and EBOV replication. These results confirm the ability of compounds identified in this study to inhibit VP35-NP interactions in vitro and to impair viral replication in cell-based assays. These studies provide an initial framework to guide development of antifiloviral compounds against filoviral VP35 proteins.",
keywords = "antivirals, filoviral inhibitors, in silico drug discovery, VP35",
author = "Brown, {Craig S.} and Lee, {Michael S.} and Leung, {Daisy W.} and Tianjiao Wang and Wei Xu and Priya Luthra and Manu Anantpadma and Shabman, {Reed S.} and Melito, {Lisa M.} and Macmillan, {Karen S.} and Borek, {Dominika M.} and Zbyszek Otwinowski and Parameshwaran Ramanan and Stubbs, {Alisha J.} and Peterson, {Dayna S.} and Binning, {Jennifer M.} and Marco Tonelli and Olson, {Mark A.} and Davey, {Robert A.} and Ready, {Joseph M.} and Basler, {Christopher F.} and Amarasinghe, {Gaya K.}",
year = "2014",
month = "5",
day = "15",
doi = "10.1016/j.jmb.2014.01.010",
language = "English (US)",
volume = "426",
pages = "2045--2058",
journal = "Journal of Molecular Biology",
issn = "0022-2836",
publisher = "Academic Press Inc.",
number = "10",

}

TY - JOUR

T1 - In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity

AU - Brown, Craig S.

AU - Lee, Michael S.

AU - Leung, Daisy W.

AU - Wang, Tianjiao

AU - Xu, Wei

AU - Luthra, Priya

AU - Anantpadma, Manu

AU - Shabman, Reed S.

AU - Melito, Lisa M.

AU - Macmillan, Karen S.

AU - Borek, Dominika M.

AU - Otwinowski, Zbyszek

AU - Ramanan, Parameshwaran

AU - Stubbs, Alisha J.

AU - Peterson, Dayna S.

AU - Binning, Jennifer M.

AU - Tonelli, Marco

AU - Olson, Mark A.

AU - Davey, Robert A.

AU - Ready, Joseph M.

AU - Basler, Christopher F.

AU - Amarasinghe, Gaya K.

PY - 2014/5/15

Y1 - 2014/5/15

N2 - The Ebola virus (EBOV) genome only encodes a single viral polypeptide with enzymatic activity, the viral large (L) RNA-dependent RNA polymerase protein. However, currently, there is limited information about the L protein, which has hampered the development of antivirals. Therefore, antifiloviral therapeutic efforts must include additional targets such as protein-protein interfaces. Viral protein 35 (VP35) is multifunctional and plays important roles in viral pathogenesis, including viral mRNA synthesis and replication of the negative-sense RNA viral genome. Previous studies revealed that mutation of key basic residues within the VP35 interferon inhibitory domain (IID) results in significant EBOV attenuation, both in vitro and in vivo. In the current study, we use an experimental pipeline that includes structure-based in silico screening and biochemical and structural characterization, along with medicinal chemistry, to identify and characterize small molecules that target a binding pocket within VP35. NMR mapping experiments and high-resolution x-ray crystal structures show that select small molecules bind to a region of VP35 IID that is important for replication complex formation through interactions with the viral nucleoprotein (NP). We also tested select compounds for their ability to inhibit VP35 IID-NP interactions in vitro as well as VP35 function in a minigenome assay and EBOV replication. These results confirm the ability of compounds identified in this study to inhibit VP35-NP interactions in vitro and to impair viral replication in cell-based assays. These studies provide an initial framework to guide development of antifiloviral compounds against filoviral VP35 proteins.

AB - The Ebola virus (EBOV) genome only encodes a single viral polypeptide with enzymatic activity, the viral large (L) RNA-dependent RNA polymerase protein. However, currently, there is limited information about the L protein, which has hampered the development of antivirals. Therefore, antifiloviral therapeutic efforts must include additional targets such as protein-protein interfaces. Viral protein 35 (VP35) is multifunctional and plays important roles in viral pathogenesis, including viral mRNA synthesis and replication of the negative-sense RNA viral genome. Previous studies revealed that mutation of key basic residues within the VP35 interferon inhibitory domain (IID) results in significant EBOV attenuation, both in vitro and in vivo. In the current study, we use an experimental pipeline that includes structure-based in silico screening and biochemical and structural characterization, along with medicinal chemistry, to identify and characterize small molecules that target a binding pocket within VP35. NMR mapping experiments and high-resolution x-ray crystal structures show that select small molecules bind to a region of VP35 IID that is important for replication complex formation through interactions with the viral nucleoprotein (NP). We also tested select compounds for their ability to inhibit VP35 IID-NP interactions in vitro as well as VP35 function in a minigenome assay and EBOV replication. These results confirm the ability of compounds identified in this study to inhibit VP35-NP interactions in vitro and to impair viral replication in cell-based assays. These studies provide an initial framework to guide development of antifiloviral compounds against filoviral VP35 proteins.

KW - antivirals

KW - filoviral inhibitors

KW - in silico drug discovery

KW - VP35

UR - http://www.scopus.com/inward/record.url?scp=84899641278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899641278&partnerID=8YFLogxK

U2 - 10.1016/j.jmb.2014.01.010

DO - 10.1016/j.jmb.2014.01.010

M3 - Article

C2 - 24495995

AN - SCOPUS:84899641278

VL - 426

SP - 2045

EP - 2058

JO - Journal of Molecular Biology

JF - Journal of Molecular Biology

SN - 0022-2836

IS - 10

ER -